This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Morgan & Morgan Announces The Investigation Of Santarus, Inc.

NEW YORK, Nov. 11, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating  potential legal claims against the board of directors of Santarus, Inc. ("Santarus" or the "Company") (NASDAQ: SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd. ("Salix").

Under the terms of the proposed transaction, Santarus stockholders will receive $32.00 in cash for each share of Santarus owned, valuing the transaction at approximately $2.6 billion.

If you own shares of Santarus and want more information about the Santarus takeover investigation please contact George Pressly, Esq. at 1(800) 631-6234 or email George at AskGeorge@morgansecuritieslaw.com.

Our investigation concerns possible breaches of fiduciary duty and other violations of law by Santarus' Board of Directors for not acting in the best interest of the Company's shareholders in connection with the sale process. 

Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:Morgan & Morgan Peter Safirstein, Esq.28 West 44 th StreetSuite 2001 New York, NY  100361-800-631-6234 info@morgansecuritieslaw.com

SOURCE Morgan & Morgan

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs